WO2000042989A3 - Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules - Google Patents

Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules Download PDF

Info

Publication number
WO2000042989A3
WO2000042989A3 PCT/US2000/001684 US0001684W WO0042989A3 WO 2000042989 A3 WO2000042989 A3 WO 2000042989A3 US 0001684 W US0001684 W US 0001684W WO 0042989 A3 WO0042989 A3 WO 0042989A3
Authority
WO
WIPO (PCT)
Prior art keywords
biologically relevant
delivery
preparation
cochleates
relevant molecules
Prior art date
Application number
PCT/US2000/001684
Other languages
French (fr)
Other versions
WO2000042989A2 (en
Inventor
Leila Zarif
Tuo Jin
Ignacio Segarra
Raphael Mannino
Original Assignee
Biodelivery Sciences Inc
Univ New Jersey Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU32133/00A priority Critical patent/AU3213300A/en
Application filed by Biodelivery Sciences Inc, Univ New Jersey Med filed Critical Biodelivery Sciences Inc
Priority to DE60035669T priority patent/DE60035669T2/en
Priority to DK00909961T priority patent/DK1143933T3/en
Priority to EP00909961A priority patent/EP1143933B1/en
Priority to JP2000594446A priority patent/JP2002535267A/en
Priority to CA2358505A priority patent/CA2358505C/en
Publication of WO2000042989A2 publication Critical patent/WO2000042989A2/en
Publication of WO2000042989A3 publication Critical patent/WO2000042989A3/en
Priority to PCT/US2001/002299 priority patent/WO2001052817A2/en
Priority to CA002397792A priority patent/CA2397792A1/en
Priority to EP01903273A priority patent/EP1259224A2/en
Priority to AU31114/01A priority patent/AU3111401A/en
Priority to JP2001552865A priority patent/JP2003529557A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Abstract

A process for producing a small-sized, lipid-based cochleate is described. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca?2+ or Zn2+¿, forms a cochleate precipitate of a particle size less than one micron. The process may be used to produce cochleates containing biologically relevant molecules. Small-sized cochleates may be administered orally or through the mucosa to obtain an effective method of treatment.
PCT/US2000/001684 1999-01-22 2000-01-24 Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules WO2000042989A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA2358505A CA2358505C (en) 1999-01-22 2000-01-24 Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
DE60035669T DE60035669T2 (en) 1999-01-22 2000-01-24 NEW CODES IN A HYDROGEL-ISOLATED COCHLEATE FORMULATIONS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE MOLECULES
DK00909961T DK1143933T3 (en) 1999-01-22 2000-01-24 Novel hydrogel-isolated cochleate formulations, method of preparation and their use in delivering biologically relevant molecules
EP00909961A EP1143933B1 (en) 1999-01-22 2000-01-24 Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
JP2000594446A JP2002535267A (en) 1999-01-22 2000-01-24 Novel hydrogel isolated cochleate formulations, methods for their preparation and uses for the administration of biologically relevant molecules
AU32133/00A AU3213300A (en) 1999-01-22 2000-01-24 Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
PCT/US2001/002299 WO2001052817A2 (en) 2000-01-24 2001-01-24 Cochleate formulations and their use for delivering biologically relevant molecules
AU31114/01A AU3111401A (en) 2000-01-24 2001-01-24 New cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
EP01903273A EP1259224A2 (en) 2000-01-24 2001-01-24 Cochleate formulations and their use for delivering biologically relevant molecules
CA002397792A CA2397792A1 (en) 2000-01-24 2001-01-24 Cochleate formulations and their use for delivering biologically relevant molecules
JP2001552865A JP2003529557A (en) 2000-01-24 2001-01-24 Cochleate formulations, methods for their preparation and uses for the administration of biologically relevant molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/235,400 US6153217A (en) 1999-01-22 1999-01-22 Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
US09/235,400 1999-01-22

Publications (2)

Publication Number Publication Date
WO2000042989A2 WO2000042989A2 (en) 2000-07-27
WO2000042989A3 true WO2000042989A3 (en) 2000-11-30

Family

ID=22885334

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/001684 WO2000042989A2 (en) 1999-01-22 2000-01-24 Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules

Country Status (12)

Country Link
US (7) US6153217A (en)
EP (1) EP1143933B1 (en)
JP (1) JP2002535267A (en)
AT (1) ATE367800T1 (en)
AU (1) AU3213300A (en)
CA (1) CA2358505C (en)
CY (1) CY1106916T1 (en)
DE (1) DE60035669T2 (en)
DK (1) DK1143933T3 (en)
ES (1) ES2290019T3 (en)
PT (1) PT1143933E (en)
WO (1) WO2000042989A2 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
WO2001052817A2 (en) * 2000-01-24 2001-07-26 Biodelivery Sciences, Inc. Cochleate formulations and their use for delivering biologically relevant molecules
DE10154464B4 (en) * 2001-11-08 2005-10-20 Max Delbrueck Centrum Orally administrable pharmaceutical preparation comprising liposomally encapsulated taxol
US20030219473A1 (en) * 2002-03-26 2003-11-27 Leila Zarif Cochleates made with purified soy phosphatidylserine
US20040092727A1 (en) * 2002-11-13 2004-05-13 Biopharm Solutions Inc. Cochleates without metal cations as bridging agents
CN1674869A (en) * 2002-08-06 2005-09-28 金拓 Cochleates without metal cations as the bridging agents
JP3927887B2 (en) * 2002-08-09 2007-06-13 本田技研工業株式会社 Stator blade of axial compressor
US8685428B2 (en) * 2002-12-10 2014-04-01 Advanced Cardiovascular Systems, Inc. Therapeutic composition and a method of coating implantable medical devices
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
WO2004064805A1 (en) * 2003-01-15 2004-08-05 Biodelivery Sciences International, Inc. Cochleate preparations of fragile nutrients
US20050013854A1 (en) 2003-04-09 2005-01-20 Mannino Raphael J. Novel encochleation methods, cochleates and methods of use
JP4789208B2 (en) 2003-04-09 2011-10-12 バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド Swirl composition for protein expression
DE10322439A1 (en) * 2003-05-19 2004-12-09 Bayer Ag Method and device for determining the isomer composition in isocyanate production processes
SE527505C2 (en) * 2003-06-10 2006-03-28 Anna Imberg Composite materials and particles
US20060188573A1 (en) * 2003-06-10 2006-08-24 Anna Imberg Composite materials and particles
EP1674093A4 (en) * 2003-10-15 2009-12-09 Nanoegg Res Lab Inc Method of controlling particle size of retinoic acid nanoparticles coated with polyvalent metal inorganic salt and nanoparticles obtained by the controlling method
CN1859906A (en) * 2003-10-15 2006-11-08 株式会社纳米卵 Composition containing retinoic acid nanoparticles coated with polyvalent metal inorganic salt
WO2005063213A1 (en) * 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
US20050244522A1 (en) * 2004-04-30 2005-11-03 Carrara Dario Norberto R Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents
US7494526B2 (en) * 2004-07-14 2009-02-24 Yavitz Edward Q Plant protection and growth stimulation by nanoscalar particle folial delivery
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US20070082115A1 (en) * 2005-10-07 2007-04-12 Aimutis William Ronald Jr Methods for inducing satiety, reducing food intake and reducing weight
US20070082030A1 (en) * 2005-10-07 2007-04-12 Aimutis William R Fiber satiety compositions
US20070082107A1 (en) * 2005-10-07 2007-04-12 Aimutis William R Jr Compositions and methods for reducing food intake and controlling weight
US20070082029A1 (en) * 2005-10-07 2007-04-12 Aimutis William R Fiber satiety compositions
WO2008024389A2 (en) * 2006-08-23 2008-02-28 Biodelivery Sciences International, Inc. Amphiphilic nucleotide cochleate compositions and methods of using the same
US20080085354A1 (en) * 2006-10-06 2008-04-10 Teresa Marie Paeschke Controlled hydration of hydrocolloids
CA2672338C (en) 2006-12-15 2017-06-06 National Research Council Of Canada Archaeal polar lipid aggregates for administration to animals
US20090054374A1 (en) * 2007-02-28 2009-02-26 Paringenix, Inc. Methods of treating acute exacerbations of chronic obstructive pulmonary disease
US8591225B2 (en) * 2008-12-12 2013-11-26 Align Technology, Inc. Tooth movement measurement by automatic impression matching
CA2694189A1 (en) * 2007-07-23 2009-01-29 University Of Utah Research Foundation Method for blocking ligation of the receptor for advanced glycation end-products (rage)
US20090047336A1 (en) * 2007-08-17 2009-02-19 Hong Kong Baptist University novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation
JP2010539245A (en) 2007-09-14 2010-12-16 日東電工株式会社 Drug carrier
ES2630805T3 (en) 2008-07-14 2017-08-24 Polypid Ltd. Sustained release drug vehicle composition
US20100113352A1 (en) 2008-11-06 2010-05-06 Elliott Millstein Retinol formulations and methods for their use
IN2012DN00570A (en) 2009-07-14 2015-06-12 Polypid Ltd
WO2011016043A2 (en) 2009-08-06 2011-02-10 Technion Research & Development Foundation Ltd. Antibiotic drug delivery and potentiation
WO2011031018A2 (en) * 2009-09-14 2011-03-17 한남대학교 산학협력단 Water-soluble drug delivery system allowing slow release
WO2011089595A2 (en) * 2010-01-19 2011-07-28 Polypid Ltd. Sustained-release nucleic acid matrix compositions
EP2533762B1 (en) * 2010-02-10 2019-03-27 Biopelle Inc. Retinol formulations and methods for their use
CN113018452A (en) 2011-04-29 2021-06-25 西莱克塔生物科技公司 Tolerogenic synthetic nanocarriers for antigen-specific deletion of effector T cells
ES2741282T3 (en) * 2011-05-05 2020-02-10 Matinas Biopharma Nanotechnologies Inc Cochleate compositions and methods of making and using them
AU2012278832B2 (en) 2011-07-06 2017-04-20 The Regents Of The University Of California Multiple-enzyme nanocomplexes
WO2013033717A1 (en) 2011-09-02 2013-03-07 The Regents Of The University Of California Enzyme responsive nanocapsules for protein delivery
LT2846809T (en) 2012-05-09 2021-01-25 Cantex Pharmaceuticals, Inc. Treatment of myelosuppression
WO2014151775A1 (en) * 2013-03-15 2014-09-25 Robert Bosch Gmbh Heated garment and battery holster
CA2910575C (en) * 2013-05-03 2023-10-24 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers and therapeutic macromolecules for reduced or enhanced pharmacodynamic effects
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
AU2016226151B2 (en) 2015-03-03 2021-02-25 Matinas Biopharma Nanotechnologies, Inc. Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent
AU2016352874B2 (en) * 2015-11-10 2021-06-24 Children's Research Institute, Children's National Medical Center Echinomycin formulation, method of making and method of use thereof
JP6991592B2 (en) * 2016-07-12 2022-01-12 マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド Treatment of co-created antifungal compounds and cryptococcal infections for central nervous system delivery
KR101989789B1 (en) 2017-11-30 2019-06-18 (주) 에이치엔에이파마켐 Cochleates using phosphatidylserine/anionic surfactant/calcium chloride
WO2020066471A1 (en) * 2018-09-28 2020-04-02 株式会社マンダム Cosmetic
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
WO2024039733A1 (en) 2022-08-16 2024-02-22 Matinas Biopharma Nanotechnologies, Inc. Methods of controlling lipid nanocrystal particle size and lipid nanocrystals produced by such methods
WO2024039729A1 (en) 2022-08-16 2024-02-22 Matinas Biopharma Nanotechnologies, Inc. Antifungal agent encapsulated in a lipid nanocrystal for treating mucormycosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840707A (en) * 1993-10-04 1998-11-24 Albany Medical College Stabilizing and delivery means of biological molecules

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4990291A (en) * 1986-04-15 1991-02-05 The United States Of America As Represented By The Secretary Of The Navy Method of making lipid tubules by a cooling process
US5269979A (en) * 1988-06-08 1993-12-14 Fountain Pharmaceuticals, Inc. Method for making solvent dilution microcarriers
AU638271B2 (en) * 1989-06-22 1993-06-24 Nexstar Pharmaceuticals, Inc. Encapsulation process
US5994318A (en) * 1993-10-04 1999-11-30 Albany Medical College Cochleate delivery vehicles
US5643574A (en) * 1993-10-04 1997-07-01 Albany Medical College Protein- or peptide-cochleate vaccines and methods of immunizing using the same
CA2246754C (en) 1996-02-22 2002-10-22 Raphael James Mannino Cochleate delivery vehicles
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840707A (en) * 1993-10-04 1998-11-24 Albany Medical College Stabilizing and delivery means of biological molecules

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALBERTSSON P -A: "AQUEOUS POLYMER-PHASE SYSTEMS", 1986, PARTITION OF CELL PARTICLES AND MACROMOLECULES,XX,XX, PAGE(S) 8-13,24-27,212-213, XP002030804 *
PAPAHADJOPOULOS D ET AL: "COCHLEATE LIPID CYLINDERS FORMATION BY FUSION OF UNI LAMELLAR LIPID VESICLES", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 394, no. 3, 1975, pages 483 - 491, XP000938443, ISSN: 0006-3002 *
ZARIF, L. ET AL: "Amphotericin B cochleates as a novel oral delivery system for the treatment of fungal infections", PROC. INT. SYMP. CONTROLLED RELEASE BIOACT. MATER. (1999), 26TH, 964-965, XP002145322 *

Also Published As

Publication number Publication date
ES2290019T3 (en) 2008-02-16
US20140220109A1 (en) 2014-08-07
US20050186265A1 (en) 2005-08-25
WO2000042989A2 (en) 2000-07-27
US6592894B1 (en) 2003-07-15
US20090028904A1 (en) 2009-01-29
JP2002535267A (en) 2002-10-22
ATE367800T1 (en) 2007-08-15
US6153217A (en) 2000-11-28
AU3213300A (en) 2000-08-07
US20030228355A1 (en) 2003-12-11
EP1143933A2 (en) 2001-10-17
CA2358505A1 (en) 2000-07-27
US20120294901A1 (en) 2012-11-22
EP1143933B1 (en) 2007-07-25
DE60035669T2 (en) 2008-02-07
CY1106916T1 (en) 2012-09-26
CA2358505C (en) 2010-04-06
PT1143933E (en) 2007-09-03
DE60035669D1 (en) 2007-09-06
DK1143933T3 (en) 2007-11-26

Similar Documents

Publication Publication Date Title
WO2000042989A3 (en) Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
US4830857A (en) Cosmetic and pharmaceutical compositions containing niosomes and a water-soluble polyamide, and a process for preparing these compositions
US5785977A (en) Non-metallic microparticle carrier materials
US7423064B2 (en) Composition for treating bacterial, viral, fungal diseases, inflammation and pain
HU202745B (en) Process for producing pharmaceutical compositions acting on the skin or percutaneously on the organism, having increased penetration capacity and comprising liposomes as active ingredient carrier
WO2001052817A3 (en) Cochleate formulations and their use for delivering biologically relevant molecules
IL174206A0 (en) Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
JP2000507958A (en) Drugs and cosmetic preparations with anti-acne activity
JPH0873342A (en) Skin external preparation or bathing agent containing rubi fructus extract
JPH0761940B2 (en) Liposomal formulation for outer skin
KR102348776B1 (en) Cosmetic composition comprising colocasia esculenta biorenovate extract and method of preparing the same
EP1996014B1 (en) Composition for treating bacterial, viral, fungal diseases, inflammation and pain
JPH11279042A (en) Skin preparation for external use
JPS6267028A (en) Skin external preparation
WO2004075906A1 (en) Antiinflammtory agent and antiinflammatory medical material
US5830914A (en) Apoptosis-controlling agent
WO1999064439A3 (en) Methods for increasing cationic antimicrobial peptides
JPH09124497A (en) Hyaluronidase inhibitor comprising ellagitannin of god type as active ingredient an medicine and cosmetic mixed with the same
US6083928A (en) Skin healing method
CN116832064A (en) Intranasal exosome composition for preventing and treating Alzheimer disease and dementia, preparation method and application thereof
CN113786394B (en) Drug delivery system for preventing and treating alopecia, preparation method thereof and microneedle patch
JP2005089390A (en) Cosmetic
JPH0469615B2 (en)
JPS6251604A (en) Dermal drug for external use
KR20170044948A (en) Cosmetic Composition For Moisturizing Skin Comprising Perna Canaliculus as Active Ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2358505

Country of ref document: CA

Ref country code: CA

Ref document number: 2358505

Kind code of ref document: A

Format of ref document f/p: F

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 32133/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 594446

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000909961

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000909961

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2000909961

Country of ref document: EP